INS and Hypoglycemia: The subsequent pursuit of attaining glycaemic targets with intensive insulin regimens requiring multiple daily injection (MDI) therapy or continuous subcutaneous insulin infusion (CSII) continues to be hindered by hypoglycaemia at all levels of glycaemic control (i.e. HbA1c) [3], thus exposing the individual to an associated and increased risk of severe hypoglycaemia [4].